What the FDA labels say about taking them together
Atorvastatin and sofosbuvir
Atorvastatin's FDA label of April 15, 2024 names sofosbuvir in its drug interactions section; the sofosbuvir label PlainMeds reads does not name atorvastatin. The atorvastatin label: “… rhabdomyolysis have been reported with concomitant use of ledipasvir plus sofosbuvir with LIPITOR.”
Check it at the source: the atorvastatin FDA label on DailyMed (effective April 15, 2024, Viatris Specialty LLC); the sofosbuvir FDA label on DailyMed (effective December 26, 2024, Gilead Sciences, Inc.).
What does the atorvastatin label say about sofosbuvir?
Atorvastatin label, drug interactionsAnti-Viral Medications Clinical Impact: Atorvastatin plasma levels were significantly increased with concomitant administration of LIPITOR with many anti-viral medications, which are inhibitors of CYP3A4 and/or transporters (…). Cases of myopathy and rhabdomyolysis have been reported with concomitant use of ledipasvir plus sofosbuvir with LIPITOR. … nelfinavir, do not exceed LIPITOR 40 mg [see ]. • Consider the risk/benefit of concomitant use of ledipasvir plus sofosbuvir with LIPITOR. • Monitor all patients for signs and symptoms of myopathy particularly during initiation of therapy and during upward dose titration of either drug. …
Atorvastatin label, warnings and precautionsCases of myopathy/rhabdomyolysis have been reported with atorvastatin co-administered with lipid modifying doses (>1 gram/day) of niacin, fibrates, colchicine, and ledipasvir plus sofosbuvir [see Adverse Reactions (6.1) ].
Source: FDA drug label (Atorvaliq, NDA213260), CMP Pharma, Inc., effective April 27, 2024 (SPL set 41fca2d8-7f3f-45b9-8974-81b89accc211), via openFDA
Source: FDA drug label (Lipitor), NDA020702 (Upjohn), as published by Viatris Specialty LLC, effective April 15, 2024 (SPL set a60cc18b-0631-4cf0-b021-9f52224ece65), via openFDA; the full label on DailyMed
What does the sofosbuvir label say about atorvastatin?
Sofosbuvir's label (effective December 26, 2024) does not name atorvastatin in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Sovaldi), Gilead Sciences, Inc., effective December 26, 2024 (SPL set 80beab2c-396e-4a37-a4dc-40fdb62859cf), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atorvastatin | Sofosbuvir | |
|---|---|---|
| Labeled for | High cholesterol, Angina, High triglycerides, Heart attack and coronary artery disease | Hepatitis C |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.0228 per tablet 10 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once